Author

T. Boyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Barthelemy· 1 shared A. Bongiovanni· 1 shared A. Plesa· 1 shared A. Zouine· 1 shared B. Le Bail· 1 shared C. Berthon· 1 shared C. PREUDHOMME· 1 shared C. ROUMIER· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Barthelemy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia

F. Gonzales, P. Peyrouze, T. Boyer, S. Guihard, F. Sevrin, D. LAURENT, A. Plesa, A. Barthelemy, A. Bongiovanni, N. Pottier, C. PREUDHOMME, N. DUPLOYEZ, C. Berthon, C. ROUMIER, M. CHEOK

This study identifies CD81 as a marker of aggressive AML and shows anti-CD81 therapy improves survival in AML models.

bioRxiv · Sep 20, 2023 · PreprintCancer Biology

TREM1+ regulatory myeloid cells expand in steatohepatitis-HCC and associate with poor prognosis and therapeutic resistance to immune checkpoint blockade

J. Giraud, D. Chalopin, E. Ramel, T. Boyer, A. Zouine, M.-A. Derieppe, N. Larmonier, O. Adotevi, B. Le Bail, J.-F. Blanc, L. Chiche, M. Nikolski, M. Saleh

This study identifies TREM1+CD163+ regulatory myeloid cells in steatohepatitis-HCC that suppress T cell function and are linked to poor prognosis and resistance to immune checkpoint therapy.

bioRxiv · Nov 9, 2022 · PreprintImmunology